Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00819663 · ClinicalTrials.gov registry record
Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography
A clinical trial of Crohn's Disease, sponsored by Mayo Clinic.
- Completed
- Registry status
- 67
- Enrollment target
- 1
- Study location
NCT00819663: Completed study of Crohn's Disease, sponsored by Mayo Clinic.
NCT00819663 is a study of Crohn's Disease that has completed, run by Mayo Clinic. The registered enrollment target is 67 participants, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00819663, a study of Crohn's Disease, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
- 1
- Study location
Study Summary
Anti-TNF therapy induces intestinal wall remodeling that correlates with clinical response and can be detected in patients undergoing serial computed tomography enterography (CTE).
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-08 |
What the finished NCT00819663 record still lists
NCT00819663 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 0 interventions.
NCT00819663 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00819663 about?
NCT00819663 is a clinical study titled "Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography". Anti-TNF therapy induces intestinal wall remodeling that correlates with clinical response and can be detected in patients undergoing serial computed tomography enterography (CTE).
What is the current status of trial NCT00819663?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2009-02. Estimated completion is 2010-08.
What conditions does trial NCT00819663 study?
This clinical trial studies the following conditions: Crohn's Disease.
Who is sponsoring clinical trial NCT00819663?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00819663 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00819663's enrollment target sits among peer trials
67 77th of 105 higher than 29 of 105 other Crohn's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease
RECRUITING · NA
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Behavioral Therapy for Crohn's Disease
RECRUITING · NA
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
RECRUITING · Phase 4
-
Helmsley 3.0: Abbreviated MRE
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia